Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MINIVELLE vs MENOSTAR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.
Estrogen receptor agonist; binds to estrogen receptors, leading to gene transcription and physiological effects.
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (use for >5 years only if clearly needed)
Treatment of moderate to severe vasomotor symptoms due to menopause,Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause
Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).
One Menostar (estradiol 14 mcg/day) transdermal system applied to the lower abdomen once weekly (every 7 days).
Terminal half-life: 12-18 hours for estradiol; clinical context: once-daily or twice-weekly dosing maintains steady-state concentrations.
Terminal half-life of estradiol is approximately 12-14 hours; with MENOSTAR (estradiol vaginal ring), systemic absorption is minimal, and the effective half-life for local effects is extended by continuous release over 90 days.
Primarily hepatic metabolism via CYP3A4 to estrone and estriol, followed by conjugation (glucuronidation, sulfation).
Hepatic via CYP3A4; undergoes enterohepatic recirculation.
Renal: 80-90% as glucuronide and sulfate conjugates; Fecal: 10-20% via bile; <1% unchanged.
Renal (primarily as glucuronide and sulfate conjugates), ~40-60% of a dose excreted in urine; fecal excretion accounts for approximately 10-20% as unabsorbed drug or metabolites.
98% bound primarily to sex hormone-binding globulin (SHBG) and albumin.
Estradiol is approximately 98% bound to sex hormone-binding globulin (SHBG) and albumin.
Approximately 1.2-1.5 L/kg; extensive distribution into tissues.
Apparent Vd of estradiol is approximately 1.2 L/kg; this large volume reflects extensive distribution into tissues, but for MENOSTAR, systemic distribution is limited due to low absorption.
Transdermal: approximately 82% of dose absorbed (avoid first-pass metabolism); oral: <5% due to extensive hepatic first-pass.
Vaginal route: minimal systemic bioavailability (<10% of the dose absorbed systemically due to first-pass hepatic metabolism and local action).
No specific dosage adjustment recommended; use with caution in severe impairment.
No dosage adjustment required for renal impairment; estradiol pharmacokinetics not significantly altered in renal disease.
Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose.
Contraindicated in patients with impaired liver function or active liver disease; no adjustment guidelines available for Child-Pugh classes.
Safety and efficacy not established; not FDA-approved for pediatric use.
Not indicated for use in pediatric patients; safety and efficacy not established.
Use lowest effective dose; monitor for thromboembolic events and malignancy; consider shorter duration.
No specific dosage adjustment recommended; however, use the lowest effective dose for the shortest duration due to increased risk of thromboembolic events and malignancy in elderly women.
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Use progestin when uterus is present. Do not use for prevention of cardiovascular disease or dementia. Increased risk of probable dementia in women ≥65 years. Increased risk of breast cancer, stroke, DVT, and pulmonary embolism.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen use increases risk of endometrial hyperplasia and carcinoma. Concomitant progestin therapy is recommended.
Cardiovascular disorders (stroke, MI, DVT), malignant neoplasms (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, exacerbation of endometriosis, and fluid retention. Minimize dose and duration.
Endometrial hyperplasia and carcinoma,Cardiovascular disorders (e.g., stroke, DVT, PE),Breast cancer risk,Gallbladder disease,Hypertriglyceridemia,Fluid retention,Hereditary angioedema
Undiagnosed abnormal genital bleeding, known/suspected breast cancer (except certain metastatic cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history thereof, active arterial thromboembolic disease (e.g., stroke, MI), known protein C/protein S/antithrombin deficiency, liver impairment or disease, known pregnancy, hypersensitivity to estradiol or components.
Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except for appropriately selected patients),Known or suspected estrogen-dependent neoplasia,Active DVT, PE, or history of these conditions,Active arterial thromboembolic disease or history of these conditions (e.g., stroke, MI),Known anaphylactic reaction or angioedema to estrogens,Hepatic impairment or disease,Known or suspected pregnancy
Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism and increase estradiol levels. St. John's wort may induce estrogen metabolism and reduce efficacy. No significant interactions with other foods.
Grapefruit and grapefruit juice may increase estradiol systemic absorption via CYP3A4 inhibition; avoid concomitant consumption. No other significant food interactions.
Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascular and urogenital defects. Second and third trimester exposure may increase risk of fetal reproductive tract abnormalities, including vaginal adenosis and clear cell adenocarcinoma in female offspring. Estrogens should not be used during pregnancy.
First trimester: Use contraindicated due to risk of urogenital tract abnormalities and cardiovascular defects; second and third trimester: Estrogen exposure associated with increased risk of endometrial adenocarcinoma and other malignancies in female offspring; no adequate studies; use only if clearly needed.
Estradiol is excreted in human breast milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. Infant exposure is considered low, but estrogens may reduce milk production and composition. Use during breastfeeding is generally not recommended, especially in the early postpartum period. Consider alternatives.
Excreted in breast milk in small amounts; M/P ratio not reported for conjugated estrogens; may interfere with lactation; not recommended in breastfeeding women; consider alternative therapy.
Estrogen metabolism is altered in pregnancy due to increased hepatic clearance and plasma volume. However, MINIVELLE is contraindicated in pregnancy; therefore, no dose adjustment recommendations are provided. Use is not advised under any circumstances.
Not indicated for use in pregnancy; no dose adjustment guidelines exist for pregnancy because of contraindication; pharmacokinetic changes in pregnancy (increased clearance, volume of distribution) may alter efficacy but no established dosing recommendations.
Minivelle (estradiol transdermal system) delivers continuous estradiol for hormone therapy. Apply to clean, dry, intact skin on lower abdomen or upper buttock; avoid breasts and waistline. Rotate application sites with at least 1-week interval. Do not apply to oily, irritated, or sunburned skin. If patch falls off, reapply or replace with a new patch; maintain same schedule. Monitor for signs of thromboembolism, stroke, or breast cancer. Discontinue if migraine develops. Use lowest effective dose for shortest duration.
MENOSTAR (estradiol vaginal ring) delivers low-dose estrogen locally for vulvovaginal atrophy. Systemic absorption minimal due to vaginal route; avoids first-pass metabolism. Insert ring high in vagina; replace every 90 days. Do not use in patients with known or suspected breast cancer, estrogen-dependent neoplasia, undiagnosed abnormal genital bleeding, active DVT/PE, or history of same. Monitor for endometrial hyperplasia in uterus intact women; consider adding progestin if needed.
Apply patch once weekly on the same day.,Choose a clean, dry area on your lower belly or upper buttock; never place on breasts.,Rotate application sites; do not use the same spot twice within 1 week.,If patch falls off, reapply a new one; if it has been off for more than 8 hours, apply a new patch and note the day.,Do not expose patch to direct heat sources (heating pads, saunas, sunbathing) as it may increase drug absorption.,Report any sudden severe headache, vision changes, chest pain, shortness of breath, or leg swelling/pain.,Avoid grapefruit juice and St. John's wort, as they may alter drug effectiveness.,Do not smoke while using this medication; smoking increases risk of blood clots and heart disease.
Insert the ring high into the vagina as directed for 90-day continuous use.,The ring may be removed during intercourse; rinse with lukewarm water and reinsert promptly.,Do not use oils or lubricants containing petroleum jelly which may damage the ring.,Report any unusual vaginal bleeding, pain, or signs of thromboembolism (leg pain, chest pain, shortness of breath).,This medication does not protect against STIs or pregnancy; no systemic contraception provided.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MINIVELLE vs MENOSTAR, answered by our medical review team.
MINIVELLE is a Estrogen Replacement that works by Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.. MENOSTAR is a Estrogen Replacement Therapy that works by Estrogen receptor agonist; binds to estrogen receptors, leading to gene transcription and physiological effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MINIVELLE and MENOSTAR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MINIVELLE is: Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).. The standard adult dose of MENOSTAR is: One Menostar (estradiol 14 mcg/day) transdermal system applied to the lower abdomen once weekly (every 7 days).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MINIVELLE and MENOSTAR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MINIVELLE is classified as Category C. Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascula. MENOSTAR is classified as Category C. First trimester: Use contraindicated due to risk of urogenital tract abnormalities and cardiovascular defects; second and third trimester: Estrogen exposure associated with increas. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.